Complications of Treatment

• Overall CV Risk Comparable After Orchiectomy, GnRHa Therapy
• Checkpoint Inhibitor Pneumonitis Risk In Metastatic Lung Cancer Independent of Thoracic Radiation
• Immune-Related Adverse Events Correlate With NSCLC Nivolumab Efficacy
• The CAN BEAR study: a systematic review and meta-analysis investigating adverse events (AEs) of targeted agents added to endocrine therapy (ET) in...
• PALOMA-2: Neutropenia (NP) Patterns in Patients (Pts) With Estrogen Receptor−Positive (ER+)/Human Epidermal Growth Factor Receptor 2−Negative (HER2...
• Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin
• Pneumocystis jiroveci pneumonia (PCP) in patients receiving weekly chemotherapy for metastatic breast cancer
• Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination
• Detection of early cardiac effects of Docetaxel Plus Trastuzumab and Pertuzumab through strain rate imaging in Patients with HER2-Positive Metastat...
• The Prognostic impact of Chemotherapy Induced Amenorrhea in Women Treated With Early Stage Breast Cancer
• OHERA – A Real World Study of Cardiac Events in >3700 Patients with HER2-positive Early Breast Cancer Treated with Trastuzumab: Final Analysis
• Incidence of permanent alopecia following adjuvant chemotherapy in women with early stage breast cancer.
• Prevention of cardiotoxicity in breast cancer patients: a randomized prospective study
• Fullerenol/iron nanocomposite modulates doxorubicin-induced cardiotoxicity
• Drug-induced electrolyte abnormalities in Oncology Phase I Trials: analysis of 1088 cases treated at The Royal Marsden Hospital
• MEK inhibitor retinopathy
• Germline Determinants of immune related Adverse Events (irAEs) in Melanoma Immunotherapy Response
• Why do grade I/II toxicities matter
• What toxicities matter to the patients
• Drug interactions that matter
• How does EMA look at toxicity/benefit ratios in cancer treatment
• Correlation of radiation pneumonitis history before nivolumab and onset risk of interstitial lung disease or progression free survival of nivolumab...
• Skin toxicities: Prevention and management
• Management of opioid induced nausea and vomiting
• Immune Related Adverse Events Associated with Ipilimumab and Nivolumab

• « Previous
• 1
• 2
• ...
• 32
• Next »